Author:
R Yogaraj,Kaur Surinder,Paarakh Padmaa M
Abstract
Oro dispersible tablets (ODTs), which have improved solubility and stability over the past three decades, have drawn a lot of interest as a superior alternative to traditional tablets and capsules. ODTs—solid dosage forms with medications that dissolve on the tongue fast, usually in a few seconds. New ODT technologies answer a wide range of pharmaceutical preparations and patient needs, to enhance the lifecycle management to straightforward dosage regimen for dysphagic, children, old, and mentally imbalanced patients. Methods for administering orally dispersible drugs are frequently used to improve patient compliance and bioavailability. Researchers in academia and business have been motivated by this to create novel technologies and orally disintegrating formulations in this field. This article's main objective was to cover the development of ODTs, formulation concerns, novel oral dispersible technology, different types of methodology to evaluate, the selection of drug candidates, and novel possibilities in future.
Reference20 articles.
1. Maniratna N, Ashok KS, Siddharth N, Madhavi G, Shiv G, Piush S. Design and formulation of fast dissolving tablet of lornoxicam using banana powder as natural super disintegrant by direct compression method. World Journal of Pharmacy and Pharmaceutical Sciences. 2018;7(2):631-42.
2. Hosny KM, Khames A, Abd Elhady SS. Preparation and evaluation of simvastatin orodispersible tablets containing soy polysaccharide and potassium polacrillin as novel superdisintegrants. International Journal of Pharmaceutical Sciences and Research. 2013 Sep 1;4(9):3381.
3. Chhajed M, Tiwari D, Malve A, Godhwani T, Chhajed A, Shrivastava AK. Formulation development and evaluation of montelukast sodium orodispersible tablets: a new trend in asthma treatment. Int J Pharm Res Sci. 2012 Aug; 1:127-39.
4. Abed KK, Hussein AA, Ghareeb MM, Abdulrasool AA. Formulation and optimization of orodispersible tablets of diazepam. Aaps Pharmscitech. 2010 Mar 1;11(1):356-61.
5. Wilson CG, Washington N, Peach J, Murray GR, Kennerlay J. The behavior of a fastdissolving dosage form (Expidet) followed by γ-scintigraphy. International Journal of Pharmaceutics, 1987; 40(1–2): 119-23.